Talquetamab
- Generic Name
- Talquetamab
- Brand Names
- Talvey
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2226212-40-2
- Unique Ingredient Identifier
- 4W3KFI3TN3
- Background
Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple...
- Indication
In the US, talquetamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In Europe, talquetamab is indicated in patients who received at least three prior therap...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT05849610
- Locations
- ๐ช๐ธ
Hospital Doce de Octubre, Madrid, Spain
๐ช๐ธHospital Clinic i Provincial de Barcelona, Barcelona, Spain
๐ช๐ธHospital Virgen de la Arrixaca, Murcia, Spain
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05757973
- Locations
- ๐ฌ๐ง
DUMMY, Dummy, United Kingdom
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT05695508
- Locations
- ๐ฉ๐ช
Charitรฉ University Medicin Berlin, Berlin, Germany
๐ฉ๐ชClinic Chemnitz gGmbH, Chemnitz, Germany
๐ฉ๐ชUniversity Clinic Technical University Dresden, Dresden, Germany
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05552222
- Locations
- ๐จ๐ณ
The Second Xiangya Hospital of Central South Hospital, Changsha, China
๐จ๐ณThe First Affliated Hospital Of Nanchang University, Nanchang, China
๐ฆ๐นSCRI CCCIT gem GmbH, Salzburg, Austria
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05503550
- Locations
- ๐ธ๐ฎ
DUMMY, Dummy, Slovenia
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05461209
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐ต๐ฑSwietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, Poland
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 810
- Registration Number
- NCT05455320
- Locations
- ๐บ๐ธ
University of Kansas, Westwood, Kansas, United States
๐บ๐ธThe Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
๐บ๐ธOhioHealth, Columbus, Ohio, United States
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 74
- Registration Number
- NCT05338775
- Locations
- ๐บ๐ธ
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธColorado Blood Cancer Institute, Denver, Colorado, United States
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 166
- Registration Number
- NCT05050097
- Locations
- ๐บ๐ธ
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธIndiana University, Indianapolis, Indiana, United States
๐บ๐ธTennessee Oncology, Nashville, Tennessee, United States
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 15
- Registration Number
- NCT04773522
- Locations
- ๐ฏ๐ต
Shonan Kamakura General Hospital, Kamakura-shi, Japan
๐ฏ๐ตNagoya City University Hospital, Nagoya, Japan
๐ฏ๐ตNational Hospital Organization Okayama Medical Center, Okayama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.